The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces rising concerns about monopolies. A few dominant companies control a significant percentage of the market, potentially limiting competition and driving up prices for consumers. This issue raises questions about the long-term impact on patient access to aff